Last edition
News about "Relapsed or Refractory Multiple Myeloma (RRMM)"
Sanofi Secures Japan Approval for Subcutaneous Formulation of Sarclisa
Sanofi’s Sarclisa subcutaneous formulation has been approved in Japan for patients with multiple myeloma. The approval is supported by the Phase 3 IRAKLIA study and marks the second global approval after the EU.
Relapsed Or Refractory Multiple Myeloma (RRMM) | 22/06/2026 | By News Bureau
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Relapsed Or Refractory Multiple Myeloma (RRMM) | 22/05/2026 | By News Bureau | 556
Pfizer's ELREXFIO Boosts Progression-Free Survival in Relapsed Multiple Myeloma
Pfizer’s ELREXFIO meets primary endpoint in MagnetisMM-5, showing significant progression-free survival benefit in relapsed/refractory multiple myeloma, with consistent safety and ongoing evaluation of Overall Survival (OS).
Relapsed Or Refractory Multiple Myeloma (RRMM) | 01/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy